Molecular Imaging: Radiopharmaceuticals for PET and SPECT

New SPECT and PET Radiopharmaceuticals for Imaging Cardiovascular Disease

Nuclear cardiology has experienced exponential growth within the past four decades with converging capacity to diagnose and influence management of a variety of cardiovascular diseases. Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) with technetium-99m radiotracers or thallium-201 has dominated the field; however new hardware and software designs that opti...

SPECT and PET radiopharmaceuticals for molecular imaging of apoptosis: from bench to clinic

Owing to the central role of apoptosis in many human diseases and the wide-spread application of apoptosis-based therapeutics, molecular imaging of apoptosis in clinical practice is of great interest for clinicians, and holds great promises. Based on the well-defined biochemical changes for apoptosis, a rich assortment of probes and approaches have been developed for molecular imaging of apopto...

Radiopharmaceuticals for Molecular Imaging

Radiopharmaceuticals for molecular imaging involve careful consideration of the following two factors: radionuclide selection and specificity to the molecular target. In selecting a radionuclide, the specific decay mode, physical half-life, chemical properties, and method of production must be considered. For proper design of a radiopharmaceutical which targets a specific biological or disease ...

Molecular Anatomic Imaging: PET/CT, PET/MR and SPECT/CT.

Molecular imaging without radiopharmaceuticals?

The limitations on the sensitivity for detecting small changes in MRI, CT, and ultrasound pulse-echo images are used to estimate the practical requirements for molecular imaging and targeted contrast enhancement for these modalities. These types of imaging are highly unlikely to approach the sensitivity for detecting molecular processes of radionuclear methods, and the prospects for achieving s...